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severity of coronary heart disease in
Chinese women
Yanmei Wang1†, Zhan Lu1†, Jingxiao Zhang1, Yang Yang2, Jing Shen3, Xiaoming Zhang4 and Yongyan Song5*

Abstract
Background: The APOA5 rs662799 polymorphism has been widely reported regarding its associations with the
plasma lipid levels and the occurrence of coronary heart disease (CHD), whereas its relationship with the severity
of CHD has not yet been explored.
Methods: Four hundred and seventy-eight angiografically defined subjects (325 CHD patients and 153 CHD-free
controls) were enrolled in this study. The rs662799 polymorphism was genotyped, and the fasting lipid data were
collected for all participants. The severity of CHD was evaluated for the CHD patients by using Gensini scores.
Results: The variant C allele of the rs662799 polymorphism was associated with lower levels of HDL-C in CHD-free
women, and higher levels of TG and TG/HDL-C in women with CHD (P < 0.05 for all). The C allele was associated
with higher prevalence of dyslipidemia and higher levels of Gensini scores only in women (P < 0.05 for both), but
not in men. Multivariate linear regression analysis showed that the rs662799 polymorphism was independently
associated with the Gensini scores in women after adjustment for other potential CHD risk factors (Beta = 0.157,
95 % CI: 0.017–0.298, P = 0.028).
Conclusion: Our data indicate that the rs662799 polymorphism is associated with dyslipidemia and the severity of
CHD in Chinese women.
Keywords: APOA5, rs662799, Coronary heart disease, Lipid, Severity

Background
Coronary heart disease (CHD) is a major cause of death
in developed countries, and in some developing countries like China [1]. CHD is recognized as a multifactorial disease, and dyslipidemia is closely associated with
the occurrence and development of CHD. It has been
demonstrated that dyslipidemia could account for
around 50 % of the population-attributable risk for CHD
[2]. Dyslipidemia is the elevation of plasma cholesterol,
triglycerides (TG), or both, or a reduction of highdensity lipoprotein cholesterol (HDL-C) that contributes
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to the development of atherosclerosis. Of the dyslipidemia components, low-density lipoprotein cholesterol
(LDL-C) can directly deposit on the walls of blood
vessels to form atherosclerotic plaques and plasma
triglycerides exert their influence on CHD by increasing
the coagulation of blood [3]. Plasma cholesterol and TG
levels are known to be affected by many factors, among
which genetic polymorphisms in the apolipoprotein
genes were considered as the key factors [4].
The APOA1/C3/A4/A5 gene cluster, located on
chromosome 11q23, has been shown to be among the
most well characterized regions of the human genome
with reference to their dynamic associations with plasma
lipid levels [5]. APOA5 is a member of the APOA1/C3/
A4/A5 gene cluster and has been recognized as a key
regulator of TG metabolism [6]. This gene is exclusively
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expressed in liver, and its product, apolipoprotein AV
(apoAV), is combined with chylomicron, very lowdensity lipoprotein (VLDL), high-density lipoprotein
(HDL), but not with low-density lipoprotein (LDL).
APOA5-knockout mice exhibited enhanced TG concentrations and conversely, APOA5-overexpressing mice
had lower TG levels than those control mice [7]. In
humans, a mutation in APOA5, which generates a truncated apoAV, has been associated with severe hypertriglyceridemia [8] and hyperchylomicronemia [9]. The
underlying mechanisms by which apoAV reduces plasma
TG and cholesterol levels are not well-known so far.
However, experimental evidence supports the view that
this apolipoprotein may function as an activator of lipoprotein lipase in the clearance of TG from the circulation [10]. Furthermore, Vu-Dac et al. [11] reported that
APOA5 is a highly responsive peroxisome proliferatoractivated receptor alpha (PPARα)-target gene and fenofibrate, a plasma TG-lowering drug, can increase the
APOA5 expression in hepatocytes by stimulating the
PPARα pathway.
Of several variants within APOA5, a transition from T
to C located upstream of the promoter of this gene
results in a rs662799 polymorphism (also known as
-1131T>C). The rs662799 polymorphism has been extensively explored regarding its associations with plasma
lipid levels and the occurrence of CHD over the past decades. In the literature, some studies demonstrated that
this polymorphism is associated with higher levels of TG
[12–25], total cholesterol (TC) [17] and LDL-C [18], and
lower levels of HDL-C [14–22]. A significant association
between this variant and the presence of CHD was also
reported in several studies [22–24, 26, 27]. However,
whether this polymorphism is associated with the severity of CHD has not been reported before.
Considering the association between the rs662799
polymorphism and dyslipidemia, it is logically plausible
to hypothesize a link between the rs662799 polymorphism and the severity of CHD. In this study, a hospitalbased study with angiographically defined CHD patients
was conducted to systematically investigate the associations of the rs662799 polymorphism with dyslipidemia,
the occurrence and severity of CHD. Our study results
can provide the opportunity to elucidate the interrelationships among the rs662799 polymorphism, dyslipidemia and CHD.

Page 2 of 9

< 0.001) and higher prevalence of menopause (P = 0.015),
dyslipidemia (P = 0.027), hypertension (P = 0.010) and diabetes (P = 0.042) than the CHD-free subjects in women.
The CHD patients had higher levels of apoB (P = 0.022),
TG/HDL-C (P = 0.036), TC/HDL-C (P = 0.001) and apoB/
apoAI (P = 0.002), and lower levels of HDL-C (P = 0.010)
and apoAI (P = 0.002) than the CHD-free subjects in men;
the CHD patients had higher levels of TG (P = 0.016), LDLC (P = 0.017), apoB (P = 0.020), TG/HDL-C (P = 0.015),
TC/HDL-C (P = 0.001), LDL-C/HDL-C (P < 0.001) and
apoB/apoAI (P = 0.004) than the CHD-free subjects in
women. The APOA5 rs662799 genotype or allele frequencies did not differ significantly between the CHD patients
and the CHD-free subjects in both men and women.
Comparisons of the clinical and biochemical variables
among the APOA5 rs662799 genotypes

The demographic variables and lipid levels among the
genotypes of the rs662799 polymorphism are shown in
Table 2 for the CHD-free subjects and in Table 3 for the
CHD patients. HDL-C (P = 0.045) levels decreased orderly with the number of C alleles in CHD-free women.
TG (P = 0.009) and TG/HDL-C (P = 0.006) levels increased orderly with the number of C alleles in women
with CHD. There were no significant differences in other
variables among the genotypes in both men and women.
The frequencies of the APOA5 rs662799 genotypes and
alleles in the non-dyslipidemic and dyslipdemic subjects

The distribution of the rs662799 genotypes and alleles
was significantly different between the non-dyslipidemic
subjects and dyslipidemic subjects in women (Table 4).
The frequencies of TC (P = 0.022) and CC (P = 0.050) genotypes were higher in the dyslipidemic women than in
the non-dyslipidemic women. The C allele frequency was
higher in the dyslipidemic women than in the nondyslipidemic women (P < 0.001). There were no significant
differences in the distribution of genotypes or alleles between the non-dyslipidemic subjects and the dyslipidemic
subjects in men.
The Gensini score levels of the CHD patients according to
the APOA5 rs662799 genotypes

As shown in Fig. 1, the Gensini score levels increased
orderly with the number of C alleles in women patients
(P = 0.045). In men patients, the Gensini score levels
were similar among the genotypes.

Results
The clinical and genetic characteristics of the study
population

As shown in Table 1, the CHD patients had higher
age (P = 0.001) and higher prevalence of dyslipidemia
(P = 0.011) and hypertension (P = 0.001) than the CHDfree subjects in men; the CHD patients had higher age (P

Linear regression analysis of the APOA5 rs662799
polymorphism and other variables with the Gensini
scores in the CHD patients

The results of the linear regression analysis of the potential CHD risk factors and the Gensini scores are
shown in Table 5. In men, univariate linear regression
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Table 1 Clinical and genetic characteristics of the study population
Men
CHD-free (n = 81)

Women
CHD (n = 205)

P

CHD-free (n = 72)

CHD (n = 120)

P

Demographic characteristics
Age, years

59.88 ± 12.58

64.63 ± 9.51

0.001

59.14 ± 9.69

64.48 ± 8.30

<0.001

Weight, kg

65.35 ± 9.43

65.58 ± 8.54

0.863

59.65 ± 9.39

59.15 ± 9.09

0.902

2

BMI, kg/m

23.58 ± 3.13

24.04 ± 3.03

0.311

24.26 ± 3.58

24.42 ± 3.68

0.507

Menopause, n (%)

NA

NA

62 (86.11)

115 (95.83)

0.015

Dyslipidemia, n (%)

49 (60.49)

155 (75.61)

0.011

32 (44.44)

73 (60.83)

0.027

Hypertension, n (%)

29 (35.80)

117 (57.07)

0.001

27 (37.50)

68 (56.67)

0.010

Diabetes, n (%)

9 (11.11)

27 (13.17)

0.636

6 (8.33)

23 (19.17)

0.042

TG, mmol/L

1.27 ± 0.67

1.58 ± 1.31

0.056

1.42 ± 0.68

1.75 ± 1.10

0.016

TC, mmol/L

3.87 ± 1.01

4.13 ± 1.21

0.087

4.11 ± 1.03

4.40 ± 1.14

0.105

Lipid levels

LDL-C, mmol/L

2.54 ± 1.85

2.61 ± 0.95

0.662

2.45 ± 0.77

2.77 ± 0.93

0.017

HDL-C, mmol/L

1.03 ± 0. 29

0.95 ± 0.23

0.010

1.11 ± 0.26

1.06 ± 0.24

0.118

ApoAI, g/L

1.08 ± 0.16

1.01 ± 0.20

0.002

1.13 ± 0.19

1.11 ± 0.18

0.394

ApoB, g/L

0.73 ± 0.24

0.81 ± 0.29

0.022

0.75 ± 0.23

0.84 ± 0.27

0.020

Lp(a), mg/L

264.04 ± 320.60

310.96 ± 332.45

0.140

239.74 ± 249.33

322.45 ± 340.38

0.087

TG/HDL-C

1.41 ± 1.03

1.82 ± 1.55

0.036

1.38 ± 0.83

1.85 ± 1.60

0.015

TC/HDL-C

3.94 ± 1.26

4.52 ± 1.35

0.001

3.75 ± 0.75

4.30 ± 1.31

0.001

LDL-C/HDL-C

2.55 ± 1.51

2.87 ± 1.10

0.052

2.24 ± 0.65

2.73 ± 1.08

<0.001

ApoB/apoAI

0.68 ± 0.25

0.85 ± 0.46

0.002

0.66 ± 0.19

0.78 ± 0.28

0.004

0.751

0.351

rs662799 Genotype frequency
TT, n (%)

43 (53.09)

103 (50.24)

42 (58.33)

63 (52.50)

TC, n (%)

33 (40.74)

90 (43.90)

28 (38.89)

51 (42.50)

CC, n (%)

5 (6.17)

12 (5.85)

2 (2.78)

6 (5.00)

rs662799 Allele frequency
T allele

0.735

0.722

C allele

0.265

0.278

0.761

0.778

0.738

0.222

0.263

0.376

CHD coronary heart disease, BMI body mass index, NA not available, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C lowdensity lipoprotein cholesterol, apoAI apolipoprotein AI, apoB apolipoprotein B

analyses were conducted and 9 viaribles [hypertension, TC, LDL-C, apoAI, apoB, Lp(a), TC/HDL-C,
LDL-C/HDL-C and apoB/apoAI] were found to be associated with the Gensini scores (P < 0.1 for all). Then
the 9 variables were taken into the stepwise multivariate
linear regression analysis and Lp(a) (P = 0.035) and apoB/
apoAI (P < 0.001) were found to be independently associated with the Gensini scores after controlling for the confounding variables including hypertension, TC, LDL-C,
apoAI, apoB, TC/HDL-C and LDL-C/HDL-C. In women,
9 viaribles [APOA5 rs662799 polymorphism, TC, LDL-C,
apoAI, apoB, Lp(a), TC/HDL-C, LDL-C/HDL-C and apoB/
apoAI] were found to be associated with the Gensini scores
in univariate linear regression analyses (P < 0.1 for all).
Then the 9 variables were taken into the stepwise multivariate linear regression analysis and APOA5 rs662799

polymorphism (P = 0.028), Lp(a) (P = 0.009) and apoB/
apoAI (P = 0.005) were found to be independently associated with the Gensini scores after controlling for the confounding variables including hypertension, TC, LDL-C,
apoAI, apoB, TC/HDL-C and LDL-C/HDL-C.

Discussion
The present study demonstrated that the rs662799
polymorphism was independently associated with the
severity of CHD in Chinese women patients. To our
knowledge, this is the first demonstration of a significant
association between the rs662799 polymorphism and the
severity of CHD, although the associations of the variant
with abnormal lipid profiles and the occurrence of CHD
have been reported in Chinese [22, 26, 27], Hungarian
[23] and Japanese [24].

Wang et al. Lipids in Health and Disease (2016) 15:170
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Table 2 Non-lipid variables and lipid levels of the CHD-free subjects by the APOA5 rs662799 genotypes
Men

Women

TT genotype
(n = 43)

CT genotype
(n = 33)

CC genotype
(n = 5)

P

TT genotype
(n = 42)

CT genotype
(n = 28)

CC genotype
(n = 2)

P

Age, years

59.44 ± 12.99

59.88 ± 12.95

63.60 ± 5.89

0.787

59.00 ± 10.86

59.29 ± 7.72

64.50 ± 7.77

0.737

Weight, kg

64.00 ± 8.87

66.53 ± 9.73

69.00 ± 12.08

0.366

59.13 ± 10.76

59.46 ± 8.92

52.50 ± 3.53

0.635

0.483

Non-lipid variables

2

BMI, kg/m

23.30 ± 3.11

23.68 ± 2.96

25.28 ± 4.67

Menopause, n (%)

NA

NA

NA

Hypertension, n (%)

14 (32.56)

13 (39.39)

2 (40.00)

Diabetes, n (%)

4 (9.30)

5 (15.15)

0 (0.00)

TG, mmol/L

1.20 ± 0.68

1.24 ± 0.50

TC, mmol/L

3.91 ± 1.08

LDL-C, mmol/L

2.73 ± 2.44

23.93 ± 4.08

24.48 ± 3.26

20.88 ± 0.85

0.404

36 (85.71)

24 (85.71)

2 (100.00 %)

0.784

0.545

12 (28.57)

14 (50.00)

1 (50.00)

0.079

0.898

2 (4.76)

4 (14.29)

0 (0.00)

0.305

2.07 ± 1.06

0.060

1.33 ± 0.65

1.58 ± 0.74

1.15 ± 0.23

0.288

3.77 ± 0.93

4.27 ± 0.68

0.554

4.30 ± 1.01

3.89 ± 1.05

3.51 ± 0.09

0.174

2.26 ± 0.75

2.73 ± 0.63

0.550

2.59 ± 0.76

2.26 ± 0.77

2.10 ± 0.00

0.161

Lipid variables

HDL-C, mmol/L

1.08 ± 0.35

0.98 ± 0.20

0.92 ± 0.25

0.264

1.18 ± 0.25

1.02 ± 0.24

0.92 ± 0.01

0.045

ApoAI, g/L

1.10 ± 0.15

1.06 ± 0.17

1.08 ± 0.17

0.705

1.16 ± 0.16

1.09 ± 0.22

0.99 ± 0.16

0.152

ApoB, g/L

0.71 ± 0.25

0.73 ± 0.24

0.85 ± 0.22

0.456

0.77 ± 0.25

0.73 ± 0.21

0.66 ± 0.10

0.680

Lp(a), mg/L

251.09 ± 323.39

280.68 ± 327.62

272.26 ± 321.52

0.926

236.26 ± 248.07

260.84 ± 271.67

211.95 ± 17.32

0.911

TG/HDL-C

1.29 ± 0.97

1.38 ± 0.78

2.62 ± 2.11

0.066

1.22 ± 0.78

1.63 ± 0.87

1.25 ± 0.25

0.131

TC/HDL-C

3.86 ± 1.43

3.91 ± 0.96

4.85 ± 1.24

0.247

3.69 ± 0.73

3.85 ± 0.82

3.83 ± 0.07

0.693

LDL-C/HDL-C

2.64 ± 1.92

2.36 ± 0.81

3.11 ± 0.92

0.506

2.23 ± 0.63

2.24 ± 0.69

2.29 ± 0.02

0.992

ApoB/apoAI

0.66 ± 0.27

0.69 ± 0.22

0.81 ± 0.22

0.424

0.66 ± 0.19

0.67 ± 0.17

0.69 ± 0.21

0.951

CHD coronary heart disease, BMI body mass index, NA not available, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C lowdensity lipoprotein cholesterol, apoAI apolipoprotein AI, apoB apolipoprotein B

The significant association between the rs662799 polymorphism and the severity of CHD was only observed in
women patients, but not in men patients. The genderspecific effects of the rs662799 polymorphism on the severity of CHD are not well understood. One reason
could be that the rs662799 polymorphism was associated
with dyslipidemia only in women (Table 4). The women
carrying one or more C alleles of the rs662799 polymorphism had higher prevalence of dyslipidemia than
those without this allele. It is logical to suppose that the
C allele carrying women experienced faster deposition of
lipids in the walls of coronary arteries and had severer
coronary stenosis than those without this allele. Another
raised question could be that why the rs662799 polymorphism was associated with higher prevalence of dyslipidemia only in women, but not in men in our study
population. This can be partly explained by the different
lifestyles between Chinese men and women. It has been
reported that the rs662799 polymorphism had interaction with lifestyles on the lipid levels in Asians [28].
The gender-specific effects of the rs662799 polymorphism on lipid levels were also reported in other populations. In Turkish adults, Komurcu-Bayrak et al. [14].
demonstrated that the C carriers had higher fasting TG

levels in both genders, but lower HDL-C levels only in
women than the non-carriers. In our study population,
the CHD-free subjects were categorized into three subgroups [subjects with normal coronary arteries, subjects
with coronary atherosclerosis and subjects with minimal
coronary stenosis (stenosis < 50 %)] according to the
extent of coronary atherosclerosis. Interestingly, there
was a weak trend in the association between the
rs662799 polymorphism and the extent of coronary atherosclerosis in CHD-free women, but not in men (data
not shown).
Our data did not support a significant association between the rs662799 polymorphism and the occurrence
of CHD, although an independent and significant association was observed between the rs662799 polymorphism
and the severity of CHD in women. This result is beyond
our understanding since a series of case–control studies
demonstrated a significant association between the
rs662799 polymorphism and the occurrence of CHD
[22–24, 26, 27]. One of the reasons could be that the
control group in our study was not made up of healthy
individuals, but the subjects who underwent angiography
for suspected CHD. In the control group, 54.90 % of
them had normal coronary arteries, 33.99 % of them had

Wang et al. Lipids in Health and Disease (2016) 15:170
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Table 3 Non-lipid variables and lipid levels of the CHD patients by the APOA5 rs662799 genotypes
Men

Women

TT genotype
(n = 103)

CT genotype
(n = 90)

CC genotype
(n = 12)

P

TT genotype
(n = 63)

CT genotype
(n = 51)

CC genotype
(n = 6)

P

Age, years

64.97 ± 9.34

64.17 ± 10.00

65.17 ± 7.60

0.827

65.17 ± 7.49

63.82 ± 9.20

62.40 ± 9.29

0.589

Weight, kg

65.71 ± 8.27

65.57 ± 9.13

64.00 ± 7.05

0.822

59.07 ± 8.14

58.59 ± 10.35

66.17 ± 5.63

0.156

0.762

Non-lipid variables

2

BMI, kg/m

24.17 ± 3.02

23.86 ± 3.10

23.81 ± 2.74

Menopause, n (%)

NA

NA

NA

24.15 ± 3.06

24.55 ± 4.48

26.59 ± 1.83

0.298

62 (98.41)

48 (94.12)

5 (83.33)

0.068

Hypertension, n (%)

57 (55.34)

55 (61.11)

5 (41.47)

0.988

42 (66.7)

23 (45.10)

3 (50.00)

0.065

Diabetes, n (%)

16 (15.53)

10 (11.11)

1 (8.33)

0.303

13 (20.6)

9 (17.65)

1 (16.67)

0.674

TG, mmol/L

1.36 ± 0.74

1.76 ± 1.73

1.83 ± 0.91

0.073

1.51 ± 0.86

1.96 ± 1.27

3.01 ± 1.55

0.009

TC, mmol/L

4.08 ± 1.18

4.24 ± 1.29

3.82 ± 0.84

0.448

4.31 ± 1.23

4.48 ± 1.03

4.44 ± 1.22

0.722

LDL-C, mmol/L

2.57 ± 0.91

2.71 ± 1.03

2.30 ± 0.61

0.307

2.70 ± 1.03

2.82 ± 0.79

2.94 ± 1.04

0.749

Lipid variables

HDL-C, mmol/L

0.96 ± 0.20

0.95 ± 0.23

0.82 ± 0.24

0.124

1.09 ± 0.24

1.03 ± 0.24

0.91 ± 0.24

0.149

ApoAI, g/L

1.00 ± 0.16

1.02 ± 0.20

1.00 ± 0.15

0.861

1.13 ± 0.16

1.08 ± 0.20

1.11 ± 0.18

0.234

ApoB, g/L

0.80 ± 0.30

0.83 ± 0.30

0.77 ± 0.19

0.618

0.80 ± 0.27

0.88 ± 0.26

0.83 ± 0.33

0.255

Lp(a), mg/L

328.47 ± 362.37

271.98 ± 285.15

412.95 ± 371.18

0.271

369.27 ± 374.08

258.82 ± 274.92

441.90 ± 437.05

0.164

TG/HDL-C

1.53 ± 1.04

1.98 ± 1.81

2.60 ± 1.78

0.057

1.52 ± 1.00

2.14 ± 2.02

3.83 ± 2.73

0.006

TC/HDL-C

4.40 ± 1.41

4.59 ± 1.30

4.86 ± 1.17

0.411

4.07 ± 1.27

4.53 ± 1.33

4.99 ± 1.19

0.080

LDL-C/HDL-C

2.80 ± 1.16

2.95 ± 1.09

2.90 ± 0.68

0.665

2.57 ± 1.08

2.88 ± 1.07

3.26 ± 0.86

0.150

ApoB/apoAI

0.85 ± 0.45

0.87 ± 0.51

0.78 ± 0.19

0.808

0.72 ± 0.26

0.84 ± 0.29

0.86 ± 0.29

0.057

CHD coronary heart disease, BMI body mass index, NA not available, TG triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C lowdensity lipoprotein cholesterol, apoAI apolipoprotein AI, apoB apolipoprotein B

consistent with the ranges reported for other Asians, including Chinese (0.29–0.39) [16, 17, 22, 26], Korean
(0.31) [15] and Japanese (0.33–0.35) [24], but is higher
than those reported for Caucasians (0.06–0.11) [13, 20,
21, 23]. The rs662799 polymorphism might have some
effects on the expression pattern of APOA5. The circulating levels of apoAV protein were affected by the
rs662799 polymorphism in several studies, but the results were inconsistent [30, 31]. Kang et al. [30] demonstrated that the C allele carriers had higher levels of
apoAV and TG than the non-carriers in type 2 diabetes
patients, whereas Jang et al. [31] reported that the C

coronary atherosclerosis and 11.11 % of them had minimal coronary stenosis (stenosis < 50 %). Some other
studies [21, 29] which demonstrated negative association
between the rs662799 polymorphism and the occurrence
of CHD also enrolled the subjects with coronary atherosclerosis or minimal coronary stenosis as controls. On
the other hand, all the studies [22–24, 26, 27] which
concluded a positive association between the rs662799
polymorphism and the occurrence of CHD used healthy
individuals as controls.
The C allele frequency of the rs662799 polymorphism
was 0.26 in the present study population, which is

Table 4 The distribution of the APOA5 rs662799 genotypes and alleles in the non-dyslipidemic and dyslipdemic subjects
Men
Non-dyslipidemic (n = 82)

Women
Dyslipidemic (n = 204)

P

Non-dyslipidemic (n = 87)

Dyslipidemic (n = 105)

P

0.280

<0.001

Genotype frequency
TT, n (%)

45 (54.88)

101 (49.51)

59 (67.82)

46 (43.81)

TC, n (%)

34 (41.46)

89 (43.63)

28 (32.18)

51 (48.57)

CC, n (%)

3 (3.66)

14 (6.86)

0 (0.00)

8 (7.62)

Allele frequency
T allele

0.756

0.713

C allele

0.244

0.287

0.299

0.839

0.681

0.161

0.319

<0.001
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and multi-ethnicities are required to validate the findings
from the present study.

Methods
Study participants

Fig. 1 The Gensini score levels of the CHD patients according to the
APOA5 rs662799 genotypes. The Gensini score levels were significantly
different among the women with different rs662799 genotypes (P < 0.05)

allele carriers had lower levels of apoAV but higher
levels of TG in healthy subjects and CHD patients.
ApoAV is combined with chylomicron, VLDL, HDL and
considered as a key regulator of TG metabolism. The
plasma levels of apoAV were reported to be negatively
associated with the TG levels [7–9]. Therefore, the association between the rs662799 polymorphism and the
severity of CHD could be mediated by apoAV and
hypertriglyceridemia.
Our findings should be considered in the context of
several potential limitations. Firstly, the small sample
size in each group may have limited the power to detect a significant relationship. Secondly, the control
group was not made up of healthy individuals, but rather the subjects who underwent angiography with
suspected CHD at our hospital, which may have led
to a selection bias. However, it was difficult to enroll
healthy subjects who underwent coronary angiography
from general population. Thirdly, the patients included in this study were exclusively Chinese Han
people, and therefore our findings may not apply to
other ethnic origins.

Conclusions
The rs662799 polymorphism is significantly associated
with dyslipidemia and the severity of CHD in Chinese
women, but further investigations with large sample size

This study was designed as a hospital-based study. A
total of 478 consecutive and unrelated adult subjects
who underwent coronary angiography for suspected
CHD at the Department of Cardiology, the Affiliated
Hospital of North Sichuan Medical College (Nanchong,
China) were enrolled in the study between April 2014
and July 2015. Of these subjects, 325 subjects were diagnosed with CHD, while the rest 153 subjects were free
of CHD and considered as the control group. Subjects
taking lipid lowering drugs or the drugs that might affect
the glucose or lipid metabolism were excluded from the
study. In order to enlarge the sample size, those who
took the drugs which were thought not to affect plasma
lipid levels were still enrolled in this study. Subjects with
renal or hepatic dysfunction, active inflammatory disease, significant valvular disease, myocarditis, and malignant disease were also excluded from the study. All the
subjects were Chinese Han people. The Han people are
the largest ethnic group in East Asia, constituting approximately 92 % of the population of Mainland China,
98 % of the population of Taiwan, and 74 % of the population of Singapore. The tenets of the Declaration of
Helsinki were adhered to in all the procedures reported
in the article. The study protocol was reviewed and
approved by the Ethics Committee of the Affiliated
Hospital of North Sichuan Medical College. Signed informed consent was provided by all the participants or
their guardians prior to their participation in the study.
Definitions

According to the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (ATP III), dyslipidemia was defined as the presence
of one or more of the following conditions: TG ≥
2.26 mmol/L, TC ≥ 6.22 mmol/L, LDL-C ≥ 4.14 mmol/L
and HDL-C < 1.04 mmol/L [32]. Smoking was defined as
regular cigarette smoking. Hypertension was defined as
the measurement of systolic/diastolic blood pressure
higher than 140/90 mmHg or active use of antihypertensive drugs. Diabetes mellitus was defined as the fasting
glucose levels above 126 mg/dL or active use of antidiabetic drugs or insulin. Body mass index (BMI) was calculated by dividing weight by height squared (kg/m2).
Biochemical measurement

Fasting blood samples were taken on the first morning of
the in-hospital day when no lipid-lowering drugs were used.
Samples were immediately shipped to the Department of
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Table 5 Linear regression analysis of the Gensini scores (dependent variable) and the potential CHD risk factors (independent
variables) in CHD patients
Variables

Men
Univariate linear
regression

Women
P

Beta (95 % CI)

Multivariate linear
regression

P

Beta (95 % CI)

Univariate linear
regression

P

Multivariate linear
regression
0.157 (0.017–0.298)

0.028

0.278 (0.071–0.486)

0.009

<0.001 0.446 (0.137–0.756)

0.005

Beta (95 % CI)

Beta (95 % CI)

APOA5
rs662799

−0.053 (−0.164–0.057)

0.342

0.187 (0.041–0.334)

0.013

Age

0.001 (−0.006–0.008)

0.777

0.008 (−0.003–0.018)

0.157

Weight

0.003 (−0.005–0.011)

0.530

−0.004 (−0.015–0.006)

0.391

BMI

0.018 (−0.004–0.041)

0.113

−0.007 (−0.003–0.019)

0.591

Menopause

NA

NA

−0.031 (−0.474–0.411)

0.889

Hypertension

0.063 (0.013–0.112)

0.013

0.001 (−0.065–0.066)

0.981

Diabetes

0.106 (−0.091–0.303)

0.289

0.021 (−0.205–0.247)

0.854

TG

−0.016 (−0.067–0.036)

0.556

0.031 (−0.047–0.109)

0.427

TC

0.059 (0.004–0.113)

0.035

0.074 (−0.003–0.151)

0.061

LDL-C

0.096 (0.027–0.165)

0.007

0.095 (0.001–0.189)

0.048

HDL-C

−0.113 (−0.401–0.176)

0.442

−0.221 (−0.586–0.143)

0.232

ApoAI

−0.384 (−0.717–
−0.051)

0.024

−0.841 (−1.330–
−0.352)

0.001

ApoB

0.372 (0.147–0.597)

0.001

0.430 (0.105–0.755)

0.010

Lp(a)

0.192 (0.038–0.346)

0.015

0.360 (0.152–0.568)

0.001

TG/HDL-C

−0.001 (−0.046–0.043)

0.957

0.012 (−0.041–0.065)

0.647

TC/HDL-C

0.073 (0.025–0.121)

0.003

0.079 (0.012–0.146)

0.021

LDL-C/HDL-C

0.101 (0.042–0.160)

0.001

0.094 (0.013–0.175)

0.024

ApoB/apoAI

0.277 (0.137–0.416)

<0.001 0.261 (0.124–0.398)

0.162 (0.012–0.312)

0.035

<0.001 0.628 (0.332–0.923)

P

CHD coronary heart disease, BMI body mass index, NA not available, 95 % CI 95 % confidence interval, TG triglycerides, TC total cholesterol, ApoAI apolipoprotein
AI, ApoB apolipoprotein B, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a)

Clinical Laboratory of the Affiliated Hospital of North
Sichuan Medical College for measurement of plasma lipids.
TG, TC, LDL-C and HDL-C were measured directly by enzymatic methods. ApoB, apoAI and Lp(a) were measured
by immunoturbidimetric assays. All the measurements
were carried out using an automatic clinical chemistry
analyzer (Beckman Coulter AU5800, USA). The lipoprotein
ratios were also calculated.
Diagnosis of CHD and evaluation of the severity of CHD

CHD was diagnosed in the patients who had angiographic evidence of stenosis greater than 50 % in at least
one major coronary artery. Those with normal coronary
arteries, coronary atherosclerosis, or minimal stenosis
(less than 50 %) in any of the major coronary arteries
were considered as CHD-free control subjects. Two experienced cardiologists who were unaware of the clinical
history and laboratory results of the subjects performed
the coronary angiography. Standard coronary angiography
with at least four views of the left coronary system and
two views of the right coronary artery was performed
using the Judkins technique by Allura Xper FD20 (Philips

Medical Systems Nederland B.V. Netherlands). The
Gensini scoring system [33] was used to assess the severity
of CHD. In this system, the lumen narrowing of coronary
arteries is graded as 1 point for 1–25 % narrowing, 2
points for 26–50 % narrowing, 4 points for 51–75 % narrowing, 8 points for 76–90 % narrowing, 16 points for
91–99 % narrowing, and 32 points for complete occlusion.
Each score is then multiplied by a factor that takes into account the importance of the lesion’s position in the coronary arterial tree, for example, 5 points for the left main
coronary artery, 2.5 points for the proximal left anterior
descending branch (LAD) or proximal left circumflex
branch (LCX), 1.5 points for the middle LAD or middle
LCX, and 1 point for the distal LAD, distal LCX or right
coronary arteries. The Gensini score was calculated as the
sum of the scores for all coronary arteries.
Statistical analysis

Continuous data were presented as mean ± standard
deviation (SD) unless otherwise stated. Continuous variables were tested for normality, and log transformation
was conducted for those which did not conform to a
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normal distribution. The differences between the CHD
patients and the CHD-free subjects, the dyslipidemic
subjects and the non-dyslipidemic subjects, or among
the subjects with different genotypes were calculated by
Chi-square test for categorical variables, and one-way
ANOVA analysis for continuous variables. The Gensini
score levels among the patients with different genotypes
were compared by one-way ANOVA analysis. The P
values were adjusted by using the Bonferroni correction
in multiple comparisons of the variables among the
rs662799 genotypes. The associations between the
rs662799 polymorphism and the other potential CHD
risk factors and the Gensini scores were analyzed by univariate and stepwise multivariate linear regression analyses; the variables with a P value less than 0.1 in
univariate analysis were taken into the multivariate analysis. The results of regression analysis were presented as
Beta with 95 % confidence interval (95 % CI). All P
values were two-tailed and the differences were considered as significant if P ≤ 0.05. All statistical analyses were
done by using 13.0 version SPSS (Chicago, IL, USA).
Abbreviations
ApoAI: Apolipoprotein AI; ApoB100: Apolipoprotein B100; BMI: Body mass
index; CHD: Coronary heart disease; HDL-C: High-density lipoprotein
cholesterol; LDL-C: Low-density lipoprotein cholesterol; Lp(a): Lipoprotein (a);
TC: Total cholesterol; TG: Triglycerides
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